PFW Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

PFW Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$229K	Sell	438 -1	-0.2%	-$512	0.07%	109
2026 Q2	$218K	Sell	439 -11	-2%	-$4.88K	0.06%	118
2026 Q1	$201K	Hold	450	–	–	0.06%	118
2025 Q4	$204K	Buy	+450	New	+$194K	0.06%	117
2025 Q3	–	Sell	-545	Closed	-$243K	–	136
2025 Q2	$243K	Sell	545 -256	-32%	-$118K	0.07%	113
2025 Q1	$388K	Hold	801	–	–	0.12%	93
2024 Q4	$323K	Buy	+801	New	+$371K	0.1%	98
2024 Q2	$377K	Sell	805 -118	-13%	-$51.2K	0.12%	94
2024 Q1	$386K	Buy	923 +1	+0.1%	+$423	0.12%	93
2023 Q4	$375K	Sell	922 -58	-6%	-$21.4K	0.12%	93
2023 Q3	$341K	Hold	980	–	–	0.12%	93
2023 Q2	$343K	Buy	+980	New	+$330K	0.11%	93
2019 Q3	$374K	Buy	+804	New	+$142K	0.11%	95

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return

PFW Advisors's VRTX Position: Q3 2026 in Review

PFW Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 0.23% in Q3 2026, selling an estimated $512 and leaving 438 shares worth $229K. The position accounts for 0.07% of the portfolio, ranked #109.

PFW Advisors first reported a position in VRTX in Q3 2019 and has held it in 13 quarters since. The position peaked at $388K in Q1 2025. 440 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

PFW Advisors held 438 shares of Vertex Pharmaceuticals worth $229K as of Q3 2026.
PFW Advisors sold 1 Vertex Pharmaceuticals share in Q3 2026, an estimated $512.
Vertex Pharmaceuticals made up 0.07% of PFW Advisors's portfolio in Q3 2026, its #109 holding.
PFW Advisors first reported a position in Vertex Pharmaceuticals in Q3 2019 and has held it in 13 quarters since.
PFW Advisors's Vertex Pharmaceuticals position peaked at $388K in Q1 2025.
440 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on PFW Advisors's 13F filing for Q3 2026, filed 7 Oct 2026.